PMID- 22500950 OWN - NLM STAT- MEDLINE DCOM- 20121012 LR - 20230124 IS - 1600-6143 (Electronic) IS - 1600-6135 (Print) IS - 1600-6135 (Linking) VI - 12 IP - 6 DP - 2012 Jun TI - Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCs. PG - 1398-408 LID - 10.1111/j.1600-6143.2012.04060.x [doi] AB - A critical goal in transplantation is the achievement of donor-specific tolerance, minimizing the use of immunosuppressants. Dendritic cells (DCs) are antigen (Ag) presenting cells (APCs) with capability to promote immunity or tolerance. The immune-regulatory properties of DCs have been exploited for generation of tolerogenic/immunosuppressive (IS) DCs that, when transfer systemically, prolong allograft survival in murine models. Surprisingly, the in vivo mechanisms of therapies based on (donor- or recipient-derived) ISDCs in transplantation remain unknown, given that previous studies investigated their effects in vitro, or ex vivo after transplantation. Since once injected, ISDCs are short-lived and transfer Ag to recipient APCs, we assessed the role of recipient DCs by depleting them at the time of ISDC-therapy in a mouse model of cardiac transplantation. The results indicate that, contrary to the accepted paradigm, systemically administered ISDCs reduce the alloresponse and prolong allograft survival, not by themselves, but through conventional DCs (cDCs) of the recipient. These findings raise doubts on the advantages of the currently used ISDC-therapies, since the immune-regulatory properties of the injected ISDC do not seem to be functionally relevant in vivo, and the quiescent/pro-tolerogenic status of cDCs may be compromised in patients with end-stage diseases that require transplantation. CI - (c) Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons. FAU - Wang, Z AU - Wang Z AD - T. E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Divito, S J AU - Divito SJ FAU - Shufesky, W J AU - Shufesky WJ FAU - Sumpter, T AU - Sumpter T FAU - Wang, H AU - Wang H FAU - Tkacheva, O A AU - Tkacheva OA FAU - Wang, W AU - Wang W FAU - Liu, C AU - Liu C FAU - Larregina, A T AU - Larregina AT FAU - Morelli, A E AU - Morelli AE LA - eng GR - R01 AI077511/AI/NIAID NIH HHS/United States GR - R01 HL077545-01A1/HL/NHLBI NIH HHS/United States GR - F30 DK082131-01/DK/NIDDK NIH HHS/United States GR - R01 HL077545-02/HL/NHLBI NIH HHS/United States GR - R01 AI077511-02/AI/NIAID NIH HHS/United States GR - R01 HL077545/HL/NHLBI NIH HHS/United States GR - F30 DK082131/DK/NIDDK NIH HHS/United States GR - R01 HL077545-04/HL/NHLBI NIH HHS/United States GR - R01 HL077545-03/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120414 PL - United States TA - Am J Transplant JT - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons JID - 100968638 RN - 0 (Immunosuppressive Agents) SB - IM CIN - Am J Transplant. 2012 Jun;12(6):1363-4. PMID: 22642470 MH - Adoptive Transfer MH - Animals MH - *Dendritic Cells MH - Enzyme-Linked Immunosorbent Assay MH - Flow Cytometry MH - Immunosuppressive Agents/administration & dosage MH - Mice MH - Mice, Inbred Strains MH - *Transplantation PMC - PMC3365643 MID - NIHMS364017 COIS- Disclosure The authors of this manuscript have no conflict of interest to disclose as described by the American Journal of Transplantation EDAT- 2012/04/17 06:00 MHDA- 2012/10/13 06:00 PMCR- 2013/06/01 CRDT- 2012/04/17 06:00 PHST- 2012/04/17 06:00 [entrez] PHST- 2012/04/17 06:00 [pubmed] PHST- 2012/10/13 06:00 [medline] PHST- 2013/06/01 00:00 [pmc-release] AID - S1600-6135(22)27470-X [pii] AID - 10.1111/j.1600-6143.2012.04060.x [doi] PST - ppublish SO - Am J Transplant. 2012 Jun;12(6):1398-408. doi: 10.1111/j.1600-6143.2012.04060.x. Epub 2012 Apr 14.